Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare Conference

Rhea-AI Summary

Aerie Pharmaceuticals (NASDAQ: AERI) announced that CFO Richard J. Rubino will present at the Oppenheimer 31^st Annual Virtual Healthcare Conference on March 17, 2021, at 8:00 a.m. ET. The presentation will offer an overview and business update for Aerie. Investors can access a live webcast on Aerie’s website, with a replay available for 10 business days. Aerie is focused on innovating ophthalmic therapies for open-angle glaucoma and ocular surface diseases. Its products include Rhopressa^® and Rocklatan^®, both aimed at reducing elevated intraocular pressure.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Richard J. Rubino, Chief Financial Officer, will present in a fireside discussion at the Oppenheimer 31^st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 8:00 a.m. Eastern Time. Mr. Rubino will provide an Aerie overview and business update.

The fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of each fireside discussion will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005024/en/

FAQ

What is the date and time of Aerie Pharmaceuticals' presentation at the Oppenheimer Conference?

Aerie Pharmaceuticals will present on March 17, 2021, at 8:00 a.m. Eastern Time.

Who will be presenting at the Oppenheimer Virtual Healthcare Conference for Aerie Pharmaceuticals?

Richard J. Rubino, Chief Financial Officer, will be presenting for Aerie Pharmaceuticals.

How can I access the Aerie Pharmaceuticals presentation?

The presentation will be webcast live and can be accessed on Aerie’s website.

What are the main products offered by Aerie Pharmaceuticals?

Aerie Pharmaceuticals offers Rhopressa^® and Rocklatan^®, both designed to treat elevated intraocular pressure.

Where can I find more information about Aerie Pharmaceuticals' products?

More information about Aerie's products can be found on their official websites for Rhopressa^® and Rocklatan^®.